新型肝脏肿瘤介入治疗后复发与转移预测方法的建立
|
摘要
目的:建立新型肝脏肿瘤射频消融治疗后复发与转移的预测方法。方法:介入治疗进展期肝细胞癌术后获得患者肿瘤组织标本,选取组织标本外围性状较好的部分,处理/加工成1~2 mm3的组织微块,接种于SCID鼠肝脏原位,在动物饲养过程中采用B超对肿瘤组织在肝脏的生长进行探查。待动物肝脏区域形成B超低回声的病灶时,收集动物获取肝脏组织,对其进行H&E染色与Masson染色的病理学分析,观察小鼠肝脏原位肿瘤的界限与包膜完整性、侵润性生长、肿瘤血管生成与是否有转移、侵袭等组织学特征。结果:H&E染色能够对肿瘤的性状进行初步判断,Masson染色能够对肿瘤细胞、微血管及纤维等结构进行分析,确定肿瘤组织的侵润性生长、肿瘤血管生成与血道转移情况,反映出临床标本中肝细胞癌细胞的生物学特性,为患者复发与转移的风险预测提供依据。结论:建立了肝脏肿瘤介入治疗后复发与转移预测方法,有望为患者预后预测提供参考。
Objective: To develop a novel method to predict the potential recurrence or metastasis of hepatocellular carcinoma(HCC) after transcatheter arterial chemoembolization(TACE) treatment. Methods: Clinical specimens were obtained from patients received TACE treatment. Tissues were seeded in SCID mice's liver organ. The intrahepatic growth of HCC in mice's liver was identified by ultrasonic detection. When HCC cells formed nodule in mice's liver organ, samples were collected and analyzed by H&E or Masson staining. Results: The infiltrative growth, tumor angiogenesis, or metastasis of HCC cells in mice's liver were identified by H&E or Masson staining.Conclusion: This work developed a novel method to be potentially palpitated in predicting the recurrence or metastasis of HCC post TACE treatment.
Objective: To develop a novel method to predict the potential recurrence or metastasis of hepatocellular carcinoma(HCC) after transcatheter arterial chemoembolization(TACE) treatment. Methods: Clinical specimens were obtained from patients received TACE treatment. Tissues were seeded in SCID mice's liver organ. The intrahepatic growth of HCC in mice's liver was identified by ultrasonic detection. When HCC cells formed nodule in mice's liver organ, samples were collected and analyzed by H&E or Masson staining. Results: The infiltrative growth, tumor angiogenesis, or metastasis of HCC cells in mice's liver were identified by H&E or Masson staining.Conclusion: This work developed a novel method to be potentially palpitated in predicting the recurrence or metastasis of HCC post TACE treatment.
引文
[1]Xu X,Fan Z,Kang L,et al.Hepatitis B virus X protein represses mi RNA-148a to enhance tumorigenesis[J].J Clin Invest,2013,123(2):630-645.
[2]Rajyaguru D J,Borgert A J,Smith A L,et al.Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients:analysis of the national cancer database[J].J Clin Oncol,2018,36(6):600-608.
[3]Ren Z,Zhu K,Kang H,et al.Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(8):894-900.
[4]Zhu A X,Rosmorduc O,Evans T R,et al.SEARCH:a phase III,randomized,double-blind,placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(6):559-566.
[5]Liu R,Zhao D,Zhang X,et al.A20 enhances the radiosensitivity of hepatocellular carcinoma cells to60Co-γionizing radiation[J].Oncotarget,2017,8(54):93103-93116.
[6]Kim D W,Talati C,Kim R.Hepatocellular carcinoma(HCC):beyond sorafenib-chemotherapy[J].J Gastrointest Oncol,2017,8(2):256-265.
[7]Zhu Y J,Zheng B,Wang H Y,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer[J].Acta Pharmacol Sin,2017,38(5):614-622.
[8]Rong G,Bai W,Dong Z,et al.Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria[J].PLo S One,2015,10(4):e0123065.
[9]Wang C,Wang H,Yang W,et al.Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma[J].Hepatology,2015,61(5):1579-1590
[10]Jia H,Yang Q,Wang T,et al.Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents[J].Biochim Biophys Acta,2016,1860(7):1417-1430.
[11]Zeng Z,Ren J,O'Neil M,et al.Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation[J].BMC Cancer,2012,12:584.
[12]Matsui Y,Horikawa M,Jahangiri Noudeh Y,et al.Baseline tumor lipiodol uptake after transarterial chemoembolization for hepatocellular carcinoma:identification of a threshold value predicting tumor recurrence[J].Radiol Oncol,2017,51(4):393-400.
[13]孙慧伟,柴燕涛,赵爽,等.一种新型肝细胞癌分子靶向治疗临床药敏检测方法的建立[J].生物技术通讯,2017,28(5):74-78.
[14]Kang J,Kim E,Kim W,et al.Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelialmesenchymal transition(EMT)by mi R-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines[J].J Biol Chem,2013,288(38):27343-27357.
[15]Feng Y,Xu X,Zhang Y,et al.HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation,apoptosis and invasion[J].Sci Rep,2015.5:9429.
[16]Xie H,Yu H,Tian S,et al.MEIS-1 level in unresectable hepatocellular carcinoma can predict the posttreatment outcomes of radiofrequency ablation[J].Oncotarget,2018,9(20):15252-15265.
[17]Zeng J,Cai X,Hao X,et al.Lnc RNA FUNDC2P4down-regulation promotes epithelial-mesenchymal transition by reducing E-cadherin expression in residual hepatocellular carcinoma after insufficient radiofrequency ablation[J].Int J Hyperthermia,2018,7:1-10.
[18]Iwahashi S,Shimada M,Utsunomiya T,et al.Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation[J].Cancer Lett,2016,375(1):47-50.
[2]Rajyaguru D J,Borgert A J,Smith A L,et al.Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients:analysis of the national cancer database[J].J Clin Oncol,2018,36(6):600-608.
[3]Ren Z,Zhu K,Kang H,et al.Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(8):894-900.
[4]Zhu A X,Rosmorduc O,Evans T R,et al.SEARCH:a phase III,randomized,double-blind,placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(6):559-566.
[5]Liu R,Zhao D,Zhang X,et al.A20 enhances the radiosensitivity of hepatocellular carcinoma cells to60Co-γionizing radiation[J].Oncotarget,2017,8(54):93103-93116.
[6]Kim D W,Talati C,Kim R.Hepatocellular carcinoma(HCC):beyond sorafenib-chemotherapy[J].J Gastrointest Oncol,2017,8(2):256-265.
[7]Zhu Y J,Zheng B,Wang H Y,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer[J].Acta Pharmacol Sin,2017,38(5):614-622.
[8]Rong G,Bai W,Dong Z,et al.Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria[J].PLo S One,2015,10(4):e0123065.
[9]Wang C,Wang H,Yang W,et al.Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma[J].Hepatology,2015,61(5):1579-1590
[10]Jia H,Yang Q,Wang T,et al.Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents[J].Biochim Biophys Acta,2016,1860(7):1417-1430.
[11]Zeng Z,Ren J,O'Neil M,et al.Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation[J].BMC Cancer,2012,12:584.
[12]Matsui Y,Horikawa M,Jahangiri Noudeh Y,et al.Baseline tumor lipiodol uptake after transarterial chemoembolization for hepatocellular carcinoma:identification of a threshold value predicting tumor recurrence[J].Radiol Oncol,2017,51(4):393-400.
[13]孙慧伟,柴燕涛,赵爽,等.一种新型肝细胞癌分子靶向治疗临床药敏检测方法的建立[J].生物技术通讯,2017,28(5):74-78.
[14]Kang J,Kim E,Kim W,et al.Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelialmesenchymal transition(EMT)by mi R-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines[J].J Biol Chem,2013,288(38):27343-27357.
[15]Feng Y,Xu X,Zhang Y,et al.HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation,apoptosis and invasion[J].Sci Rep,2015.5:9429.
[16]Xie H,Yu H,Tian S,et al.MEIS-1 level in unresectable hepatocellular carcinoma can predict the posttreatment outcomes of radiofrequency ablation[J].Oncotarget,2018,9(20):15252-15265.
[17]Zeng J,Cai X,Hao X,et al.Lnc RNA FUNDC2P4down-regulation promotes epithelial-mesenchymal transition by reducing E-cadherin expression in residual hepatocellular carcinoma after insufficient radiofrequency ablation[J].Int J Hyperthermia,2018,7:1-10.
[18]Iwahashi S,Shimada M,Utsunomiya T,et al.Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation[J].Cancer Lett,2016,375(1):47-50.